W Fraser Symmans

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma
    W Fraser Symmans
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:2960-71. 2003
  2. ncbi A pathologist's perspective on emerging genomic tests for breast cancer
    W Fraser Symmans
    Department of Pathology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 34:S4-9. 2007
  3. ncbi Maximum predictive power of the microarray-based models for clinical outcomes is limited by correlation between endpoint and gene expression profile
    Chen Zhao
    The Center for Bioinformatics and The institute of Biomedical Sciences, School of Life Sciences, East China Normal University, Shanghai, 200241, China
    BMC Genomics 12:S3. 2011
  4. ncbi Maximizing biomarker discovery by minimizing gene signatures
    Chang Chang
    The Center for Bioinformatics and Institute of Biomedical Sciences, School of Life Science, East China Normal University, 500 Dongchuan Road, Shanghai 200241, China
    BMC Genomics 12:S6. 2011
  5. ncbi Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer
    Ana M Gonzalez-Angulo
    Departments of Breast Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Clin Proteomics 8:11. 2011
  6. ncbi Effect of training-sample size and classification difficulty on the accuracy of genomic predictors
    Vlad Popovici
    Bioinformatics Core Facility, Swiss Institute of Bioinformatics, Genopode Building, Quartier Sorge, Lausanne CH 1015, Switzerland
    Breast Cancer Res 12:R5. 2010
  7. ncbi Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response
    Qiyuan Li
    Center for Biological Sequence Analysis, Department of Systems Biolology, Technical University of Denmark, 2800 Lyngby, Denmark
    BMC Bioinformatics 12:310. 2011
  8. ncbi Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment
    W F Symmans
    Department of Pathology, and Kaplan Comprehensive Cancer Center, New York University Medical Center, New York 10016, USA
    Clin Cancer Res 6:4610-7. 2000
  9. ncbi A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding
    W F Symmans
    Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Endocr Relat Cancer 12:1059-69. 2005
  10. ncbi Genomic index of sensitivity to endocrine therapy for breast cancer
    W Fraser Symmans
    Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 28:4111-9. 2010

Research Grants

  1. ER Reporter Genes To Predict Response To Endocrine Therapy
    WILLIAM SYMMANS; Fiscal Year: 2007

Collaborators

Detail Information

Publications79

  1. ncbi Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma
    W Fraser Symmans
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:2960-71. 2003
    ..This study compared gene expression profiles derived from fine-needle aspiration biopsy (FNAB) and from core needle biopsy (CBX)...
  2. ncbi A pathologist's perspective on emerging genomic tests for breast cancer
    W Fraser Symmans
    Department of Pathology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 34:S4-9. 2007
    ..However, the challenge will be to bring the best results from this exciting research into clinical use as accurate and reliable standardized tests that integrate into the diagnostic work-up...
  3. ncbi Maximum predictive power of the microarray-based models for clinical outcomes is limited by correlation between endpoint and gene expression profile
    Chen Zhao
    The Center for Bioinformatics and The institute of Biomedical Sciences, School of Life Sciences, East China Normal University, Shanghai, 200241, China
    BMC Genomics 12:S3. 2011
    ..Fine-tuning of model parameters and optimizing each step of the modeling process often results in over-fitting problems without improving performance...
  4. ncbi Maximizing biomarker discovery by minimizing gene signatures
    Chang Chang
    The Center for Bioinformatics and Institute of Biomedical Sciences, School of Life Science, East China Normal University, 500 Dongchuan Road, Shanghai 200241, China
    BMC Genomics 12:S6. 2011
    ....
  5. ncbi Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer
    Ana M Gonzalez-Angulo
    Departments of Breast Medical Oncology and Systems Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Clin Proteomics 8:11. 2011
    ..abstract:..
  6. ncbi Effect of training-sample size and classification difficulty on the accuracy of genomic predictors
    Vlad Popovici
    Bioinformatics Core Facility, Swiss Institute of Bioinformatics, Genopode Building, Quartier Sorge, Lausanne CH 1015, Switzerland
    Breast Cancer Res 12:R5. 2010
    ....
  7. ncbi Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response
    Qiyuan Li
    Center for Biological Sequence Analysis, Department of Systems Biolology, Technical University of Denmark, 2800 Lyngby, Denmark
    BMC Bioinformatics 12:310. 2011
    ..However, identification of clinically predictive or prognostic classifiers can be challenging when a large number of genes are measured in a small number of tumors...
  8. ncbi Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment
    W F Symmans
    Department of Pathology, and Kaplan Comprehensive Cancer Center, New York University Medical Center, New York 10016, USA
    Clin Cancer Res 6:4610-7. 2000
    ..This is a promising start toward the development of an early chemopredictive assay for paclitaxel treatment of breast cancer...
  9. ncbi A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding
    W F Symmans
    Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Endocr Relat Cancer 12:1059-69. 2005
    ..036). GABApi gene expression is increased in breast cancers of immature (undifferentiated) cell type and is significantly associated with shorter lifetime history of breastfeeding and with high-grade breast cancer in Hispanic women...
  10. ncbi Genomic index of sensitivity to endocrine therapy for breast cancer
    W Fraser Symmans
    Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 28:4111-9. 2010
    ..We hypothesize that measurement of gene expression related to estrogen receptor α (ER; gene name ESR1) within a breast cancer sample represents intrinsic tumoral sensitivity to adjuvant endocrine therapy...
  11. ncbi Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy
    W Fraser Symmans
    Department of Pathology, Unit 85, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 25:4414-22. 2007
    ..To measure residual disease after neoadjuvant chemotherapy in order to improve the prognostic information that can be obtained from evaluating pathologic response...
  12. ncbi Breast cancer response to paclitaxel in vivo
    F W Symmans
    Department of Pathology, The UT M D Anderson Cancer Center, Houston, Texas 77030, USA
    Drug Resist Updat 4:297-302. 2001
    ..Knowledge of breast cancer response to paclitaxel in vivo could lead to therapeutic strategies that enhance the apoptotic response and optimize the dosing schedule, to improve the tumor reduction for most patients...
  13. ncbi What is the role of cytopathologists in stereotaxic needle biopsy diagnosis of nonpalpable mammographic abnormalities?
    W F Symmans
    Department of Pathology, New York University Medical Center, New York, New York, USA
    Diagn Cytopathol 24:260-70. 2001
    ..The main advantage for including cytologic methods with stereotaxic breast biopsy is immediate sample assessment, and this advantage can also be applied to core needle procedures...
  14. ncbi Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers
    Christos Hatzis
    Nuvera Biosciences, Woburn, MA, USA
    J Natl Cancer Inst 103:1871-83. 2011
    ..Reliable stability and yield of RNA from breast cancer tissues are important for biobanking, clinical trials, and diagnostic testing...
  15. ncbi CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Breast Cancer Res 9:R87. 2007
    ..We performed gene expression analysis to identify molecular predictors of resistance to preoperative concomitant trastuzumab and paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (T/FEC)...
  16. ncbi Breast cancer molecular subtypes respond differently to preoperative chemotherapy
    Roman Rouzier
    Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA
    Clin Cancer Res 11:5678-85. 2005
    ..CONCLUSIONS: The basal-like and erbB2+ subtypes of breast cancer are more sensitive to paclitaxel- and doxorubicin-containing preoperative chemotherapy than the luminal and normal-like cancers...
  17. ncbi Evaluation of biological pathways involved in chemotherapy response in breast cancer
    Attila Tordai
    Department of Breast Medical Oncology, The University of Texas M, d, Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    Breast Cancer Res 10:R37. 2008
    ..Our goal was to examine the association between biological pathways and response to chemotherapy in estrogen receptor-positive (ER+) and ER-negative (ER-) breast tumors separately...
  18. ncbi Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 27:4287-92. 2009
    ..Expression levels were correlated with disease-free survival (DFS) and overall survival (OS). Interaction between this marker and paclitaxel efficacy was also examined...
  19. ncbi Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
    Kenneth R Hess
    Department of Biostatistics and Applied Mathematics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77230-1439, USA
    J Clin Oncol 24:4236-44. 2006
    ..This test correctly identified all but one of the patients who achieved pCR (12 of 13 patients) and all but one of those who were predicted to have residual disease had residual cancer (27 of 28 patients)...
  20. ncbi Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response
    Radhika Rajan
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030-4009, USA
    Cancer 100:1365-73. 2004
    ....
  21. ncbi Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 100:1814-22. 2004
    ..The authors also compared the plasma profiles of patients with cancer with the plasma profiles of healthy women to identify breast carcinoma-associated protein markers...
  22. ncbi Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77230-1439, USA
    J Clin Oncol 23:8331-9. 2005
    ..72 in the validation set and outperformed other prediction tools (P = .02). CONCLUSION: Our nomograms predict pCR accurately and can serve as a basis to integrate future molecular markers into a clinical prediction model...
  23. ncbi Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
    Cornelia Liedtke
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 1439, USA
    J Clin Oncol 26:1275-81. 2008
    ..In this study, we compared response to neoadjuvant chemotherapy and survival between patients with TNBC and non-TNBC...
  24. ncbi Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy
    Florentia Peintinger
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg Oncol 13:1443-9. 2006
    ..Agreement of residual tumor size in mammography and sonography with pathologic residual tumor size was moderate...
  25. ncbi Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers
    Giampaolo Bianchini
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 28:4316-23. 2010
    ....
  26. ncbi Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer
    Abigail S Caudle
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 28:1821-8. 2010
    ..Because many of these variables are also associated with response to NCT, novel molecular predictors are needed to identify patients at risk for progression on standard NCT...
  27. ncbi Development of candidate genomic markers to select breast cancer patients for dasatinib therapy
    Stacy Moulder
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 9:1120-7. 2010
    ..We defined three conceptually different potential predictors of dasatinib response that were reproducible across cell lines and human data. These candidate markers are being tested in a clinical trial to determine their utility...
  28. ncbi PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer
    Cornelia Liedtke
    Department of Breast Medical Oncology, University of Texas M, d, Anderson Cancer Center, Houston, TX, USA
    Breast Cancer Res 10:R27. 2008
    ..In vitro evidence suggests that PIK3CA (phosphatidylinositol 3-kinase, catalytic, alpha polypeptide) activation may be associated with altered chemotherapy sensitivity in cancer...
  29. ncbi Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks
    Marjorie C Green
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 424, Houston, TX 77030, USA
    J Clin Oncol 23:5983-92. 2005
    ....
  30. ncbi The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy
    Florentia Peintinger
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 107:1248-54. 2006
    ..Prospective studies are needed to examine whether decreasing the RVs in this patient population leads to an increased LRR rate...
  31. ncbi Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers
    Charles Coutant
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Clin Cancer Res 17:2591-601. 2011
    ..We hypothesized that p53 mutations may lead to different transcriptional changes and carry different prognostic value in these two different types of cancers...
  32. ncbi Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines
    Cornelia Liedtke
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, BO Box 301439, Houston, TX 77030 1439, USA
    Breast Cancer Res Treat 121:301-9. 2010
    ..Cell line-derived predictors of response to four commonly used chemotherapy drugs did not predict response accurately in patients...
  33. ncbi Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer
    Roman Rouzier
    Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 102:8315-20. 2005
    ..Low tau expression may be used as a marker to select patients for paclitaxel therapy. Inhibition of tau function might be exploited as a therapeutic strategy to increase sensitivity to paclitaxel...
  34. ncbi Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer
    Florentia Peintinger
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:4078-82. 2007
    ..We examined whether the response predicted by a 30-gene pharmacogenomic test correlated with the residual cancer burden (RCB) after preoperative chemotherapy with paclitaxel, 5-fluorouracil, doxorubicin, and cyclophosphamide (T/FAC)...
  35. ncbi Use of lymphoscintigraphy defines lymphatic drainage patterns before sentinel lymph node biopsy for breast cancer
    Kazumi Kawase
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Coll Surg 203:64-72. 2006
    ..Longterm followup of patients with lymphoscintigraphic evidence of extraaxillary drainage is needed to determine whether regional and systemic recurrence patterns differ in these patients...
  36. ncbi Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy
    Linda J Adepoju
    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:42-50. 2006
    ..Concurrent ADH, ALH, or LCIS with DCIS is not a contraindication to BCT...
  37. ncbi Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ
    Tina W F Yen
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Coll Surg 200:516-26. 2005
    ..Risks and benefits of SLNB should be discussed with patients who are younger, are diagnosed by core-needle biopsy, or have large or high-grade DCIS...
  38. ncbi Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma
    Fan Zhang
    Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1758-65. 2003
    ..CONCLUSIONS: The authors found no significant correlation between HER-2 expression and clinical or pathologic response to neoadjuvant chemotherapy in patients with breast carcinoma...
  39. ncbi Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome
    Chafika Mazouni
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 25:2650-5. 2007
    ..To determine whether residual ductal carcinoma in situ (DCIS) after completion of preoperative chemotherapy affects the outcome of patients with histologically defined complete eradication of invasive cancer...
  40. ncbi Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 26:4679-83. 2008
    ....
  41. ncbi Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors
    Lajos Pusztai
    Departments of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 009, USA
    Clin Cancer Res 9:2406-15. 2003
    ..33)P]dCTP-labeled cDNA probes were generated and hybridized to cDNA membrane microarrays that contained 30,000 human sequence clones, including 10,890 expressed sequence tags...
  42. ncbi Global gene expression changes during neoadjuvant chemotherapy for human breast cancer
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer J 8:461-8. 2002
    ..A remarkable diversity in transcriptional response was observed for individual cases. Further data are needed to determine whether gene profiling can predict response to chemotherapy...
  43. ncbi Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer J 9:33-41. 2003
    ..We investigated whether changes in tumor cell apoptosis and Bcl-2 expression immediately after chemotherapy correlated with response to breast cancer treatment...
  44. ncbi Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy
    Min Yi
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:916-24. 2011
    ..The purpose of this study was to examine the rates of local, regional, and systemic recurrence, and survival in breast cancer patients who underwent skin-sparing mastectomy (SSM) or conventional mastectomy (CM) at our institution...
  45. ncbi Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry
    Takayuki Iwamoto
    The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 30:729-34. 2012
    ....
  46. ncbi Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer
    Shivani S Shinde
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:4933-43. 2010
    ....
  47. ncbi Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer
    Takayuki Iwamoto
    Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Breast Cancer Res Treat 125:785-95. 2011
    ..IBC tumors can be divided into molecular and clinical subtypes similar to those of non-IBC. Clinical subtypes of IBC show molecular differences compared with similar subtypes of non-IBC...
  48. ncbi Molecular classification of breast cancer: limitations and potential
    Lajos Pusztai
    D Phil, University of Texas M D Anderson Cancer Center, Department of Breast Medical Oncology, Unit1354, PO Box 301439, Houston, Texas 77230 1439, USA
    Oncologist 11:868-77. 2006
    ..To provide context for this discussion, we also briefly examine the performance of estrogen receptor immunohistochemistry, which represents an essential part of the routine diagnostic workup for all breast cancer patients...
  49. ncbi Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations
    Yun Gong
    Department of Pathology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Am J Clin Pathol 131:490-7. 2009
    ..0% among 3 sites using the manufacturers' criteria and 100.0% between 2 sites using the ASCO/CAP criteria. Our results confirm that CISH is reliable for HER2 testing per ASCO/CAP guidelines...
  50. ncbi Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer
    Stacy L Moulder
    Department of Breast Medical Oncology, Pathology, Surgical Oncology, Radiation Oncology and Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:7909-16. 2008
    ..We evaluated the efficacy and safety of a Bcl-2 antisense oligonucleotide, G3139, in combination with doxorubicin (A) and docetaxel (T) in patients with locally advanced breast cancer (LABC)...
  51. ncbi Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:1195-200. 2007
    ..The purpose of this study was to review the efficacy and safety of a similar regimen outside the setting of a clinical trial...
  52. ncbi First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations
    Takayuki Iwamoto
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, 77230 1439, USA
    Breast Cancer Res Treat 130:155-64. 2011
    ..First-generation prognostic-gene signatures predict both chemotherapy response and long-term survival. When multiple predictors are applied to the same case discordant risk prediction frequently occurs...
  53. ncbi Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer
    Ana M Gonzalez-Angulo
    Departments of Breast Medical Oncology, Systems Biology, Biostatistics, Surgical Oncology, and Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 18:1109-19. 2012
    ..We removed stroma-associated genes to minimize confounding effects. PAM50 was used to assign molecular class. Paired t test and gene set analysis were used to identify differentially expressed genes and pathways...
  54. ncbi Reproducibility of gene expression signature-based predictions in replicate experiments
    Keith Anderson
    Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77230-1439, USA
    Clin Cancer Res 12:1721-7. 2006
    ..016), respectively. CONCLUSION: Gene expression results obtained with Affymetrix U133A chips are highly reproducible within and across two high-volume laboratories. Pharmacogenomic predictions yielded >90% agreement in replicate data...
  55. ncbi Classification of ipsilateral breast tumor recurrences after breast conservation therapy can predict patient prognosis and facilitate treatment planning
    Min Yi
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, TX, USA
    Ann Surg 253:572-9. 2011
    ..We utilized 2 different methods and compared sensitivities and specificities between them. Our goal was to determine whether distinguishing NP from TR had prognostic value...
  56. ncbi Histologic localization of sentinel lymph node metastases in breast cancer
    Leslie K Diaz
    Department of Pathology, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Am J Surg Pathol 27:385-9. 2003
    ..This information may be useful in determining the optimal method for evaluating axillary sentinel lymph node specimens from breast cancer patients...
  57. ncbi Metastases to the breast from nonbreast solid neoplasms: presentation and determinants of survival
    Stephanie A Williams
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    Cancer 110:731-7. 2007
    ..The purpose of this study was to identify clinical characteristics and outcomes associated with this entity to identify determinants of survival...
  58. ncbi Prognostic value of initial clinical disease stage after achieving pathological complete response
    Shaheenah Dawood
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030 4009, USA
    Oncologist 13:6-15. 2008
    ..Overall, patients who achieved a pCR had a low rate of recurrence. However, higher clinical stage and IBC were associated with worse outcomes in breast cancer patients who achieved a pCR after PST...
  59. ncbi Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer
    Adel Tabchy
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Clin Cancer Res 16:5351-61. 2010
    ..We compared the pCR rates after T/FAC versus FACx6 preoperative chemotherapy. We also did an exploratory analysis to identify novel candidate genes that differentially predict response in the two treatment arms...
  60. ncbi Molecular profiles of invasive mucinous and ductal carcinomas of the breast: a molecular case study
    Lajos Pusztai
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Genet Cytogenet 141:148-53. 2003
    ..Taken together, these data suggest that expression profiling can be used diagnostically to distinguish individual histologic subclassifications and may guide the selection of target therapeutics...
  61. ncbi Long-term outcomes in patients with mucinous, medullary, tubular, and invasive ductal carcinomas after lumpectomy
    Thao Vo
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Am J Surg 194:527-31. 2007
    ..In this study, we evaluated the long-term outcomes of breast-conserving therapy (BCT) for these subtypes of breast cancer and compared them with those for invasive ductal carcinoma...
  62. ncbi Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems
    Kenneth R Hess
    Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, USA
    BMC Bioinformatics 12:463. 2011
    ..Prediction models were trained to identify which cases had been perturbed. Performance was estimated using Monte-Carlo cross validation...
  63. ncbi B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells
    Rita Nahta
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Mol Cancer Ther 5:1593-601. 2006
    ..These results suggest that BTG1 is a Bcl-2-regulated mediator of apoptosis in breast cancer cells, and that its induction contributes to antisense Bcl-2-mediated cytotoxic effects...
  64. ncbi Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study
    Yun Gong
    Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 8:203-11. 2007
    ..Our goal was to establish a new method to assign oestrogen receptor and ERBB2-receptor status to breast carcinoma based on mRNA expression measured using Affymetrix U133A gene-expression profiling...
  65. ncbi Optimal fixation conditions for immunocytochemical analysis of estrogen receptor in cytologic specimens of breast carcinoma
    Yun Gong
    Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 102:34-40. 2004
    ..Air-drying, destaining Pap smear, and fixation in formalin or Carnoy's-Pap without antigen retrieval are not recommended...
  66. ncbi Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis
    Xiaohong Leng
    Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA
    Cancer Res 69:8579-84. 2009
    ..Our results suggest that inhibition of LCN2 function by an inhibitory monoclonal antibody has potential for breast cancer therapy, particularly by interfering with metastasis in aggressive types of breast cancer...
  67. ncbi Gene-expression microarrays provide new prognostic and predictive tests for breast cancer
    Yun Gong
    University of Texas, Department of Pathology, Anderson Cancer Center, Unit 53, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Pharmacogenomics 8:1359-68. 2007
    ..This review focuses on the recent progression in feasibility and reliability of gene-expression microarrays in identifying new prognostic and predictive indicators of breast cancer...
  68. ncbi Intraoperative touch imprint of sentinel lymph nodes in breast carcinoma patients
    Andrea Lee
    Department of Pathology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 96:225-31. 2002
    ..The difficulty of identifying micrometastases appeared to be the major source of false negative events, a problem that is not unique to TI cytology...
  69. ncbi Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 13:228-33. 2007
    ..All data were updated through November 2005...
  70. ncbi RefSeq refinements of UniGene-based gene matching improve the correlation of expression measurements between two microarray platforms
    Yuan Ji
    Department of Biostatistics and Applied Mathematics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA
    Appl Bioinformatics 5:89-98. 2006
    ..It is a sensible approach for matching probes across platforms.We conclude that UniGene alone is insufficient to match genes across platforms. Refined matching based on RefSeq significantly improves the quality of matches...
  71. ncbi Ductal carcinoma in situ: state of the science and roadmap to advance the field
    Henry M Kuerer
    The University of Texas M D Anderson Cancer Center, DCIS Discovery Program and Department of Surgical Oncology, 1515 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
    J Clin Oncol 27:279-88. 2009
    ..Understanding of the biology and clinical behavior of DCIS is imperfect. This article highlights the current knowledge base and the scientific roadmap needed to advance the field...
  72. ncbi Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer
    Lajos Pusztai
    Box 424, Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    J Clin Oncol 21:3454-61. 2003
    ..We studied the safety and clinical activity of exisulind in combination with capecitabine in 35 patients with metastatic breast cancer (MBC)...
  73. ncbi Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria
    Yun Gong
    Department of Pathology, Unit 53, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Am J Clin Pathol 132:228-36. 2009
    ..1%, respectively; when using the ASCO/CAP criteria, the values were 96.7%, 97.3%, and 97.4%, respectively. These results indicate that CISH is reliable for testing these 2 types of tumors, especially when the ASCO/CAP criteria are used...
  74. ncbi Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible?
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Unit 424, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Drug Resist Updat 7:325-31. 2004
    ..Perhaps, the most important challenge is to prospectively design and conduct validation trials that demonstrate clinical utility by showing improved patient outcomes with the use of a proposed new test...
  75. ncbi Implications of axillary sentinel lymph node biopsy in immediate autologous breast reconstruction
    Steven J Kronowitz
    Department of Plastic and Reconstructive Surgery, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Plast Reconstr Surg 109:1888-96. 2002
    ..New developments in breast cancer diagnosis and treatment necessitate a team approach, with increased communication between the breast surgeon and the plastic surgeon in planning surgery for these patients...
  76. ncbi Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer
    Lei Wang
    Department of Molecular Pathology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Res 63:4724-30. 2003
    ..The correlation of the nuclear localization and invasion suppression function of Syk(L) indicated that nuclear Syk possesses biological activities associated with tumor suppression in mammary epithelial cells...
  77. ncbi An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
    Katherine Stemke-Hale
    Department of Systems Biology, The University of Texas MD Anderson Cancer, Houston, Texas 77030, USA
    Cancer Res 68:6084-91. 2008
    ..The specific aberration present may have implications for the selection of PI3K-targeted therapies in hormone receptor-positive breast cancer...
  78. ncbi Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cells
    Ana M Tari
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lab Invest 85:1357-67. 2005
    ..Here we report the novel findings that COX-2 uses PGE2 to stimulate the activities of protein kinases A and C to induce selectively tamoxifen and 4-HPR resistance in ERalpha-positive breast cancer cells...
  79. ncbi Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease
    Julie R Gralow
    Seattle Cancer Care Alliance, Department of Medicine, 825 Eastlake Ave, EMS G3 200, Seattle, WA 98109 1023, USA
    J Clin Oncol 26:814-9. 2008
    ..To review the state of the science with respect to preoperative systemic therapy and pathologic assessment in operable breast cancer...

Research Grants1

  1. ER Reporter Genes To Predict Response To Endocrine Therapy
    WILLIAM SYMMANS; Fiscal Year: 2007
    ....